Para-aminosalicylate sodium (PAS)

Select language:
Permalink
On this page

    Update: October 2022

     

    Forms and strengths 

    • Powder for oral solution, 5.52 g sachet of para-aminosalicylate sodium (equivalent to 4 g PAS acid), to be dissolved in 100 ml water

    Dosage (expressed in PAS acid)

    • Child under 30 kg: 100 to 150 mg/kg 2 times daily
    • Child 30 kg and over and adult: 4 g 2 times daily (max. 12 g daily)

     

    Weight
    (kg)

    Daily dose
    (mg)

    Oral solution or sachet

    PAS sodium 

    5

    1000-1500

    19 ml x 2

    6

    1200-1800

    19 ml x 2

    7

    1400-2100

    25 ml x 2

    8

    1600-2400

    25 ml x 2

    9

    1800-2700

    25 ml x 2

    10

    2000-3000

    50 ml x 2

    11

    2200-3300

    50 ml x 2

    12

    2400-3600

    50 ml x 2

    13

    2600-3900

    50 ml x 2

    14

    2800-4200

    50 ml x 2

    15

    3000-4500

    50 ml x 2

    16

    3200-4800

    75 ml x 2

    17

    3400-5100

    75 ml x 2

    18

    3600-5400

    75 ml x 2

    19

    3800-5700

    75 ml x 2

    20

    4000-6000

    75 ml x 2

    21

    4200-6300

    75 ml x 2

    22

    4400-6600

    75 ml x 2

    23

    4600-6900

    75 ml x 2

    24

    4800-7200

    80 ml x 2

    25

    5000-7500

    80 ml x 2

    26

    5200-7800

    80 ml x 2

    27

    5400-8000

    80 ml x 2

    28

    5600-8000

    80 ml x 2

    29

    5800-8000

    80 ml x 2

     

    30-70

    8 g

    1 sachet x 2

    > 70

    8-12 g

    1 to 1½ sachet x 2

     

    Contra-indications, adverse effects, precautions

    • Avoid in patients with severe renal disease.
    • Avoid or use with caution in patients with hepatic impairment or gastric ulcer.
    • May cause :
      • frequent gastrointestinal disturbances (nausea, vomiting, gastritis, diarrhoea);
      • hypothyroidism, hepatotoxicity, hypersensitivity reactions.
    • Monitor combination with ethionamide/prothionamide (increased risk of gastrointestinal disturbances and hypothyroidism).
    • For the management of adverse effects, see Apendix 17.
    • Pregnancy: use only if benefits outweigh the risks (safety not established).p
    • Breastfeeding: avoid breastfeeding during treatment (safety not established).

    Monitoring

    • Symptomatic monitoring.
    • Liver and thyroid function.

    Patient instructions

    • Mix the powder with 100 ml water.
    • Take with food to limit gastrointestinal disturbances.

    Remarks

    • To increase gastrointestinal tolerance, start with a low dose, e. g. for an adult : 2 g 2 times daily for 1 to 2 weeks, then 4 g 2 times daily.

    Storage

     
    –  
     
    –  Below 25 °C